Brief: Virios Therapeutics Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Dogwood Therapeutics

02/01/2024 12:33

Jan 2 (Reuters) - Virios Therapeutics Inc  VIRI.O :
    * VIRIOS THERAPEUTICS, INC. REACHES ALIGNMENT WITH FDA ON
REQUIREMENTS FOR ADVANCING DEVELOPMENT CANDIDATE IMC-2 AS
TREATMENT FOR LONG-COVID
    * VIRIOS THERAPEUTICS INC: FDA RECOMMENDED ASSESSMENT OF
RANGE OF
IMC-2 DOSES, INCLUDING VALACYCLOVIR DOSES ABOVE PRESENTLY
APPROVED DOSAGE STRENGTHS
    * VIRIOS THERAPEUTICS INC: CURRENTLY EXPLORING OPTIONS TO
ADVANCE
IMC-2 LC PHASE 2 RESEARCH PROGRAM

Source text for Eikon:  ID:nGNX6rJbbV 
Further company coverage:  VIRI.O 

 ((Reuters.Briefs@thomsonreuters.com;))